Since 2005, ClearScript has partnered with our clients to help them achieve the lowest net cost and an exceptional service experience while improving their members’ well-being. Learn why we are the clear choice in pharmacy benefit management.
You need a partner, not a vendor. ClearScript’s collaborative business model allows us to produce pharmacy benefit plans tailored to our clients’ needs and goals; not a one-size-fits-all like other PBMS. Let us show you how.
With ClearScript, you will never sacrifice savings for service. ClearScript’s cost savings may get us in the door, but our service keeps us there. See for yourself!
As we reflect on the developments of 2023 and set our sights on 2024, the pharmacy benefit landscape is undergoing significant transformations. Read on to learn what ClearScript is watching in this evolving and complex field to stay ahead of changes that will impact the pharmacy benefit.
On November 8, 2023, Eli Lilly announced the approval of the newest weight loss drug Zepbound, a much-anticipated formulation of tirzepatide in the high-profile GLP-1 agonist medications class. Used along with reduced calorie diet and exercise, studies have shown Zepbound can lead to significant weight loss.
ClearScript’s Vice President of Clinical Operations, Yalda Olcott, PharmD, presents an educational look at how GLP-1 drugs are driving plan spend including their indications, benefits, industry insight, and strategies for navigating these drugs in your benefit plan.
In 2023, the U.S. Food & Drug Administration (FDA) approved three new vaccines for the prevention of Respiratory Syncytial Virus (RSV). RSV is a highly contagious, common respiratory virus that typically causes mild cold-like symptoms. However, it can cause serious illness in older adults and infants.
Amidst growing public and government attention on insulin affordability, what do plan sponsors need to know as they plan coverage strategies in 2024 and beyond?
As more people are lured to these medications with hopes of an effective weight loss solution, many plan sponsors are growing concerned about their impact on plan spend.
The launch of Amjevita, the first FDA-approved biosimilar for Humira, is big news for pharmacy benefit plan sponsors.
An estimated 8 million adults in the U.S. have psoriasis. Last month, the FDA approved Sotyktu (deucravacitinib), the first in a new class of oral medication to treat plaque psoriasis. Will this new product be revolutionary or evolutionary when it comes to plaque psoriasis therapy?
Alzheimer’s drug pipeline news: Biogen Inc. in partnership with Eisai Co. has released encouraging data about their new anti-amyloid monoclonal antibody therapy (lecanemab) currently in clinical trials.